**Core tip:** In this review, we summarized the literature and our recent findings on liver damage associated with co-infection with human immunodeficiency virus (HIV) and hepatotropic viruses \[hepatitis C virus (HCV), hepatitis B virus (HBV)\]. The combination of HIV with HCV or HBV causes progressive liver injury and chronic liver inflammation ultimately leading to end-stage liver disease, such as cirrhosis and hepatocellular carcinoma. These outcomes are related to many events including apoptosis-mediated cross-talk between liver parenchymal and non-parenchymal cells, accumulation of inflammatory cells in the liver, microbial translocation and impaired immune responses. The treatment of these co-infections requires the combination of direct acting antiviral (DAA) and antiretroviral therapy (ART) for HCV + HIV and comparatively high doses of DAA for HBV, which should be controlled for drug-drug interactions to avoid hepatotoxicity.

INTRODUCTION
============

Human immunodeficiency virus (HIV)-related liver disease has become one of the most common causes of increased non-acquired immune deficiency syndrome (AIDS) mortality in HIV-infected people\[[@B1]\]. Major co-morbidities that drive this liver disease progression are co-infections with hepatotropic viruses as well as alcohol and drug abuse. Recently, we published a review article on the mechanisms of liver cells targeting by HIV and the role of alcohol in potentiation of hepatocyte permissiveness to HIV-infection\[[@B2]\]. Here, we overview another crucial factor *i.e*., co-infection with hepatotropic viruses, such as hepatitis B virus (HBV) and hepatitis C virus (HCV) that promotes liver injury progression. We will also address the therapeutic strategies to reduce HIV-mediated liver damage in the presence of these co-morbidities that could ultimately mitigate/prevent the development of end-stage liver disease.

HIV/HCV CO-INFECTION INDUCED LIVER INJURY
=========================================

It has been reported that of 170 million people chronically infected with HCV, 4 to 5 million persons are co-infected with HIV worldwide\[[@B3]-[@B7]\]. As estimated, up to 25% of HIV- infected population in the United States are also co-infected with HCV\[[@B8]\]. Co-infection with HCV and HIV has been associated with a faster progression of hepatitis and a higher liver-related mortality even in the era of antiretroviral therapy (ART)\[[@B9],[@B10]\]. The exact role of HCV-infection in the natural history of HIV-infection is not clear. As reported, while HCV infection is not associated with an increase in AIDS-related events or deaths, co-infected individuals may have lower CD4^+^ T cell counts as compared to HIV-mono-infected patients\[[@B11],[@B12]\]. In contrast, HIV co-infection produces numerous adverse effects by increasing replication of HCV\[[@B13]\], slowing down the HCV clearance, enhancing fibrogenesis\[[@B14]\] and decreasing the response to direct acting antiviral (DAA) treatment\[[@B10]\], ultimately increasing liver dysfunction and incidence of death. Eyster et al\[[@B15]\] compared the levels of HCV RNA before and after HIV-seroconversion in HCV-infected patients and reported that HCV RNA levels were enhanced 8-fold in patients co-infected with HIV compared to HCV mono-infected. Furthermore, CD4^+^ T cell count in these patients correlated with the levels of HCV RNA. In contrast to the 20% HCV RNA clearance because of acute HCV mono-infection, only 5%-10% of HIV/HCV co-infected patients were able to successfully clear the virus\[[@B16],[@B17]\]. Although ART does not directly inhibit HCV replication, the progression of liver disease is reduced in the settings of co-infection by HIV replication inhibition and by CD4^+^ cell count increase\[[@B18],[@B19]\]. Furthermore, ART enhances HCV-specific T cell responses concurrently with a significant decrease in HCV-RNA levels\[[@B20]\]. In addition, liver-related mortality and hepatic decompensation were shown to be reduced in ART-treated HIV-positive patients with chronic viral hepatitis. Low CD4^+^ cell counts and a failure to achieve the complete suppression of HIV replication are the risk factors of liver-related death\[[@B21],[@B22]\]. Importantly, the progression to fibrosis in HIV/HCV-co-infected patients is reduced by ART. However, acute and long-term ART-associated hepatotoxicity occurs more frequently in HIV/HCV-co-infected persons since simultaneous ART-DAA treatment is toxic than either treatment with each kinds of drugs alone and is generally not well-tolerated by patients\[[@B23],[@B24]\]. Thus, the opposing effects of ART in mitigating or worsening liver disease in HIV/HCV-co-infected patients have been reported.

The mechanisms by which HIV/HCV co-infection accelerate the liver disease are not well understood. In our recent *in vitro* study, we observed that hepatocytes co-infected with HIV and HCV expressed higher levels of HCV RNA and HIV RNA than mono-infected cells. Importantly, an enhanced viral RNA expression in co-infection was even more potent in cells exposed to pan-caspase inhibitor since double-infections caused significant hepatocyte apoptosis\[[@B25]\]. In the same study, plating hepatocytes on 2D gels that recapitulated varying liver stiffness revealed that the increased stiffness was accompanied by a higher HCV/HIV RNA and up-regulation of hepatocyte apoptosis in co-infected cells. Our *in vitro* data suggests that co-infections potentially may enhance hepatocyte apoptosis in patients with liver fibrosis. These events can further perpetuate disease progression based on our studies demonstrating that engulfment of these apoptotic hepatocytes by hepatic stellate cells promotes fibrogenesis\[[@B25]\]. Aforementioned *in vitro* results were supported by a recent report on increased liver disease severity in HIV/HCV co-infected patients, particularly in patients with elevated liver stiffness\[[@B9]\]. For diagnosing of liver fibrosis/cirrhosis, there is a tendency now to reduce the number of liver biopsies (especially, in United States). Thus, liver stiffness is determined by Fibroscan, and the distribution of liver stiffness by cutoff is reported as as follows: \< 7.1 kPa (absent or mild liver fibrosis), 58.0%; \> 9.5 kPa (advanced fibrosis), 23.3%; and \> 12.5 kPa (cirrhosis)\[[@B26]\]. The search for non-invasive parameters to predict the fibrosis progression becomes an important goal for monitoring HIV/HCV co-infected patients. As indicated, co-infection with HIV and HCV demonstrated an immunosuppressive profile compared to HIV-mono-infection, and in advanced cirrhosis patients, (stiffness \> 25 kPa), was associated with the lowest plasma values of T-helper 1 and T-helper 17 response\[[@B27]\]. Furthermore, transient elastography evaluated in a prospective study on a cohort of 154 HCV/HIV co-infected patients identified that elevated alanine amino aspartate (AST) level and liver stiffness at the baseline were increased in individuals under the risk of fibrosis progression\[[@B28]\].

Both HIV and HCV cause inflammation, playing an important role in the development of liver diseases in co-infected patients\[[@B29]-[@B31]\]. This inflammation is linked to endothelial dysfunction\[[@B32]\] since there is evidence that cytokine and chemokine production increased the expression of cell adhesion molecules and induce cellular infiltration to the sites of hepatic infection, which finally contributes to tissue damage and fibrosis in HIV/HCV co-infected patients\[[@B33]\]. These studies were confirmed by the researchers from two independent groups who demonstrated that the pro-inflammatory effects on HCV replication were amplified by HIV/HCV co-infection\[[@B34]\] by causing an increase in the levels of cell adhesion molecules, soluble vascular cell adhesion molecule-1 (sVCAM1) and soluble intercellular adhesion molecule-1 (sICAM1), to induce endothelial dysfunction and develop decompensated cirrhosis and death\[[@B9]\]. There is a link between liver inflammation and fibrosis development. Thus, transforming growth factor beta1 (TGF-β1), a central mediator of liver fibrogenesis, is a regulatory cytokine released by numerous cell types during inflammation\[[@B35]\]. In this regard, HIV/HCV co-infection induces a significant increase in TGF-β1 in patients' liver and serum\[[@B7],[@B36],[@B37]\]. In addition, HIV-gp120 may directly influence hepatic necro-inflammation and fibrosis in HIV/HCV co-infection.

Liver infiltration with immune cells plays a key role in fibrosis progression. Thus, CD4^+^ T- regulatory cells and activated HIV-specific CD8^+^ T cells detected in the livers of HIV-1/HCV co-infected patients may promote liver fibrosis *via* the secretion of tumor necrosis factor alpha (TNFα)\[[@B38]\] or by direct induction of TNFα-related apoptosis-inducing ligand (TRAIL)\[[@B39]\]. In fact, immune activation at HIV-1 infection is associated with increased circulating levels of TRAIL and with TRAIL-induced apoptosis in CD4^+^ T-cell\[[@B40],[@B41]\]. Hence, the combination of chronic HIV-1 infection with HCV-associated inflammatory changes may result in increased intrahepatic TRAIL levels followed by increased susceptibility of hepatocytes, lymphocytes, Kupffer cells and hepatic stellate cells (HSCs) to TRAIL-mediated apoptosis\[[@B42]-[@B44]\].

In HIV/HCV co-infection, oxidative stress is one of the key factors to cause liver injury. It has been demonstrated that the magnitude of oxidative stress and liver injury were more pronounced in HIV/HCV co-infection than in HIV mono-infection\[[@B45],[@B46]\]. Huang et al\[[@B47]\] reported that HIV/HCV co-infection aggravated liver damages compared with HCV mono-infection, and a linkage between HIV-induced oxidative stress and higher incidence rate of advanced liver disease was found in co-infected patients. The same authors indicated that the worsening of liver fibrosis status in HIV/HCV-co-infected patients may be associated with HIV- infection and related, in part, to higher levels of oxidant markers, such as oxidized glutathione and malondialdehyde. In agreement with this report, previous studies also confirmed that the increased levels of oxidative stress markers, including oxidized glutathione, malondialdehyde, 8-hydroxy-2\'-deoxyguanosine, activities of electron transport chain enzymes, complex I and complex IV, decreased antioxidants, and impaired mitochondrial transmembrane potential have been observed in HIV/HCV co-infection\[[@B48]-[@B53]\]. Moreover, oxidative stress-elicited acceleration of fibrosis and cirrhosis may be a consequence of a long-term exposure to circulating pro-oxidant components induced by HIV/HCV co-infection, which further influences the hepatic microenvironment in HCV-infected patients\[[@B47]\].

Another major cause of systemic immune activation in HIV and HCV mono-infection is the bacterial translocation, which accelerates liver damage in HIV/HCV co-infected patients\[[@B31]\]. The mechanism of liver fibrosis promotion by microbial translocation in HIV/HCV co-infection is associated with activation of liver macrophages and HSC: (1) directly by microbial products, resulting in the secretion of pro-fibrotic cytokines; or (2) indirectly *via* induction of systemic immune responses and promotion of local hepatocyte activation-induced apoptotic death resulting in collagen deposition\[[@B54]\]. Normally, bacterial translocation products are cleared by liver macrophages, resident Kupffer cells, but, the clearance of these products is compromised by HIV-infection\[[@B55]\], which may cause phenotypic/functional changes or depletion of Kupffer cells.

Collectively, the mechanisms to drive the progressive liver disease in HCV/HIV co-infection are multi-component and include HIV-1-induced immune suppression due to CD4^+^ T-cell depletion, systemic immune activation, increased lymphocyte and hepatocyte apoptosis, oxidative stress, impaired anti-HCV immune responses, promotion of retroviral infection of HSCs and Kupffer cells and microbial translocation. Altogether, it contributes to the increased rates of liver fibrosis\[[@B5]-[@B7]\].

HIV/HBV CO-INFECTION-INDUCED LIVER INJURY
=========================================

Worldwide, about 10% of all people infected with HIV are also chronically co-infected with HBV\[[@B4],[@B56]\]. For two large European and North American HIV treatment cohorts, the prevalence of HBV co-infection was reported as 8.7% and 7.6%, respectively\[[@B57]\]. HBV and HIV have common routes of transmission in endemic areas, though HBV is about 100 times more infectious than HIV\[[@B58]-[@B60]\]. Morbidity and mortality in HIV/HBV co-infections is higher than in mono-infections\[[@B61],[@B62]\]. The development of chronic HBV infection in HIV-infected patients is age-dependent: while only \< 5% of adults negative for HIV acquire chronic HBV-infection, HBV infection chronically persists in 25% of those co-infected with HIV in adulthood and in 50%-90% of those who were exposed to HIV at birth or in early childhood\[[@B63]\].

Co-infection with HIV completely changes the natural history of HBV-infection since higher serum HBV DNA levels were accompanied by higher rates of cirrhosis, especially in HIV patients with low CD4^+^ T cell counts\[[@B64],[@B65]\]. Lipopolysaccharide (LPS) serum levels are elevated in HIV/HBV co-infected patients, likely predisposing to similar intrahepatic inflammation and fibrosis\[[@B66]\]. Interestingly, HBV has been shown to suppress TLR-mediated innate immune responses leading to activation of pro-inflammatory cytokines\[[@B67]\]. This could have implications for the development of liver fibrosis during HIV co-infection, but there are no current studies to clarify this issue. TGF-β expression has also been associated with liver fibrosis in HBV-infected patients, but its role in HIV-co-infected patients has not been addressed\[[@B68]\]. In contrast to HIV/HCV co-infection, liver fibrosis mediated through apoptosis-related receptors do not play a key role in HIV/HBV co-infection. It has been hypothesized that HIV alters HBV-specific immune response by affecting the hepatic cytokine environment, thereby promoting liver fibrosis and disease progression; however, this hypothesis has not been thoroughly tested\[[@B69],[@B70]\]. In HIV/HBV co-infection, it is difficult to determine the stage of liver disease\[[@B71]\]. Liver biopsy remains the best method for disease staging because non-invasive measures of hepatic fibrosis have not been broadly used in these patients\[[@B72]\]. The incidence of liver fibrosis in HIV/HBV co-infected patients exceeds by 3-fold when compared to HIV-monoinfected individuals\[[@B73]\]. Liver fibrosis progression and regression were evaluated as endpoints with respect to an extensive list of determinants: host characteristics (age, alcohol consumption *etc*.), HIV and HBV viral suppression, immunosuppression, antiretroviral and antiviral therapy, biomarkers of HIV/HBV-related liver disease and surrogates of metabolic disorders\[[@B74]\].

In general, HIV infection worsens the course and progression of hepatitis B more than vice versa\[[@B75]\]. The main HIV proteins responsible for activation of cell metabolism trans-activator of transcription (TAT), viral turnover (Vpr), and attachment of virus to cell surface/induction of cell death (gp120), are released from HIV-infected cells and are detectable in the plasma of AIDS patients\[[@B76]\]. These proteins are captured by many cell types, including hepatocytes, thereby accelerating HBV-induced fibrosis and HCC development\[[@B77],[@B78]\]. It has been reported that HIV-induced immunosuppression increases HBV antigen titers, including HBsAg, HBeAg and HbxAg, finally leading to the aggravation of hepatitis\[[@B79]\]. It appears paradoxical that HBV related liver damage, which is an immune‐mediated process, is exacerbated by the HIV-mediated immunodeficient state\[[@B69]\]. However, there are several possible reasons for this paradoxical relationship. In HIV‐infected persons, a rapidly progressive form of liver disease known as fibrosing cholestatic hepatitis, has been attributed to viral cytopathic effect rather than to the immune response\[[@B80]\]. Hence, it is possible that HBV-induced chronic active hepatitis develops not due to anti-HBV-specific immune response, but due to cytotoxic effects of HIV or HIV-induced mutations in HBV, which, in turn, increase HBV cytotoxic properties\[[@B81],[@B82]\]. Studies by Revill et al\[[@B81]\] supported the hypothesis about a novel mutation in the pre-core/core region of the HBV genome and found it to be more common among HIV/HBV co-infected than HBV mono-infected individuals. In fact, co-infected persons with this mutation have higher HBV DNA levels than those without the mutation\[[@B69]\].

As shown previously, there are elevated levels of circulating LPS in HIV/HBV co-infected individuals compared with uninfected controls and HBV monoinfected individuals, but no direct correlation was determined between elevated circulating LPS and liver fibrosis\[[@B66]\]. These observations are consistent with the results of similar studies in HIV/HCV co-infection\[[@B83],[@B84]\]. It is possible that for driving liver disease progression, the concentration of LPS in the portal vein and/or in the liver may be more important than LPS levels in peripheral blood. Recent studies in simian immunodeficiency virus (SIV)-infected rhesus macaques suggested that an increased microbial load in the liver can also trigger chemokine production and upregulate infiltration with CXCR6^+^-activated natural killer cells, which may contribute to liver fibrosis\[[@B85]\]. It has been reported that the chemokine CXCL10, a chemokine and a ligand for CXCR3 expressed on activated T cells, is associated with elevations in liver enzymes in HIV/HBV co-infection and may contribute to liver disease *via* migration of activated T-cells to the liver\[[@B61],[@B66]\]. Inhibition of these chemokines may potentially reduce liver disease in HIV/HBV co-infection and should be further explored\[[@B61]\]. It has been reported that HIV- infects productively Kupffer cells, alters their response to translocated microbial products, which breaks their tolerance\[[@B86]\] and may promote hepatic inflammation and fibrosis in HIV-HBV co-infected patients.

The pathogenesis of HIV/HBV co-infection is based on the properties of both viruses and is influenced by differential human cell populations in the liver, which are permissive for each infection. In this regard, HBV, being by itself not a cytopathogenic virus, requires activation of immune response for elimination of HBV-infected hepatocytes. Concordantly, immune cells and namely, CD4^+^ T-lymphocytes and macrophages, are HIV-permissive and cause disruptions in both innate and adaptive immunity. This disbalance between high infectivity of HBV in hepatocytes and HIV-weaken immune response in the liver is a key feature of HBV/HIV co-infection pathogenesis and a suggested target for co-infection treatment. Thus, the most suitable in vivo model for the studies of co-infection pathobiology and therapeutic applications should combine human hepatocytes and human immune cells, including liver resident macrophages (Kupffer cells) and lymphocytes, which can cross-talk in the settings of both infections.

In HIV/HCV co-infection, the progression to liver cirrhosis and HCC may take about 10-20 years and has been demonstrated even in case of HCV eradication by successful DAA treatment. Thus, a large multi-center study from Spain has reported HCV-related cirrhosis in 7.6% of HIV-infected individuals, and out of them 15% of patients had active HCV, while 31.5% of were those who cleared HCV after anti-HCV therapy\[[@B26]\]. The conclusion from this study was that the burden of HCV-related cirrhosis in HIV-infected patients was very significant even if overall morbidity and mortality was reduced by HCV elimination in this patient cohort. The mechanisms why cirrhosis is progressing in some patients or can be stopped in some individuals currently are not clear. While HCC development also reduced by DAA, HCV/HIV co-infected patients with advanced cirrhosis is still represent a risk group for this outcome, with the highest risk of HCC progression in DAA non-responders. Thus, the heterogenicity of these cirrhotic patients based on various co-morbidities, genetic polymorphism\[[@B87]-[@B89]\], late treatment initiation and altered response to treatment may affect the end-stage liver disease progression in coinfected patients.

TREATMENT OF HIV/HCV AND HIV/HBV CO-INFECTIONS WITH ART AND DAA
===============================================================

As reported, ART delays the progression to cirrhosis in HIV/HCV co-infection\[[@B90],[@B91]\]. Patients with undetectable or low levels of HIV RNA tend to develop liver disease gradually compared to patients with detectable viremia\[[@B92],[@B93]\]. Furthermore, HIV treatment reduces the complications of the end-stage liver diseases, such as hepatocellular carcinoma (HCC) and death\[[@B94]-[@B96]\]. Hence, as per European and United States guidelines, ART is recommended for co-infected patients regardless of CD4^+^ T cell count\[[@B94],[@B97]\]. Nevertheless, co-infected patients with advanced liver disease experience a higher pill burden as well as an increased risk of drug-drug interactions and drug-induced liver injury regardless of sustained virologic response (SVR) during simultaneous HCV and HIV therapy\[[@B98]-[@B100]\]. Therefore, treatment-of naïve HIV/HCV co-infected patients with CD4^+^ T cell counts \> 500 cells/μL requires treating HCV first, and delaying HIV treatment to reduce the potential for drug toxicity and interactions\[[@B94]\]. For those patients on ART who are likely to be subsequently treated with DAA for HCV, the treatment regimens should be chosen with an assessment of potential drug-drug interactions with the planned HCV therapy in the future. For example, HIV integrase inhibitors, such as dolutegravir and raltegravir, have relatively few drug-drug interactions, while use of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors might preclude the use of some DAA for HCV treatment, particularly those targeting the HCV protease.

In most of co-infected patients, DAA-based therapy was shown as safe and effective. However, according to the results of the large real-world study, the predictors of failure included male gender, HIV-related immunosuppression, high HIV RNA load, severity of liver disease and suboptimal DAA-based regimens\[[@B101]\]. Baseline NS5A resistance (NS5A RAS) is associated with suppressed response to DAA in HCV-infected patients\[[@B102],[@B103]\]. While low rates of HCV recurrence in HCV/HIV patients after DAA treatment was reported, this outcome cannot be totally excluded\[[@B104]\]. Reinfection by HCV (with other virus genotypes) following successful DAA treatment is also possible\[[@B105]\]. Eradication of HCV by anti-viral therapy does not guarantee prevention of continuous liver injury and fibrosis development and often depends on the stage of fibrosis at the time when the treatment started: it is more successful at early stage of fibrosis and less successful at the later stages\[[@B26],[@B106]\]. In United States, the Veterans Affairs (VA) National Health Care System has the best experience in treating of co-infected patients with DAA since DAA treatment is available for all HCV-infected patients, thereby revolutionizing the treatment outcomes. As the negative predictors of sustained viral response at week 12 (SVR 12), VA studies have reported African-American race/ethnicity and advanced liver disease\[[@B107]\]. At VA national trials, they found high SVR in patients treated with ledispavir/sofosbuvir and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)\[[@B108]\]. In this study, SVR was achieved in 92.8% of genotype 1 HCV patients, 86.2% genotype 2 patients, 74.8% genotype 3 patients and 89.8% genotype 4 patients. Dependence of sensitivity to DAA on HCV genotype was confirmed by other studies: in 1150 co-infected individuals treated with sofosbuvir plus ribavirin, sofosbuvir plus ledipasvir and sofosbuvir plus daclatasvir, SVR was achieved in 91-100% patients; the lowest response was in genotype 3 patients that have cirrhosis (88%) (reviewed by\[[@B109]\]). DAA-based therapy (in combination with ribavirin in half of patients) was generally well tolerated in a Spanish cohort of HIV/HCV co-infected individuals with compensated cirrhosis, with only 1.2% stopping due to adverse events, and the SVR12 rate was the highest among those without cirrhosis (93.5%) compared with those with compensated (91.2%) or decompensated cirrhosis (80.8%) (reviewed by\[[@B109]\].

In HIV/HBV-co-infected patients, early initiation of ART, including the drugs active against both HIV and HBV, is recommended. Among the antiretroviral drugs with dual activity, tenofovir is the preferred choice due to its high potency and high genetic barrier to resistance\[[@B110],[@B111]\]. Wit et al\[[@B23]\] showed that previously, every licensed antiretroviral drug has been associated with liver enzyme elevation. The panel of drugs used for the co-infection treatment includes tenofovir, lamivudine, emtricitabine, entecavir, and adefovir at the doses \> 10 mg\[[@B112]\]. However, the combination of drugs efficient for both viruses is very toxic since hepatocytes are not only infected by viruses, but also are the sites of drug metabolism. The role of hepatocytes in handling toxic drug substances makes them vulnerable to drug-induced liver injury (hepatotoxicity) and consequently, to cell death\[[@B113],[@B114]\]. Powderly et al\[[@B115]\] analyzed many drugs used for therapy of HIV/HBV co-infection, including, lamivudine and tenofovir. The results of this study indicated that since HIV/HBV co-infected patients received the combined therapy rather than individual drugs, considerable attention should be paid to hepatotoxic properties of these drugs.

A recent prospective multicenter cohort study found no difference in virologic response between patients with and without lamivudine resistance at baseline throughout 5 years of therapy with tenofovir, emphasizing tenofovir's suitable resistance profile\[[@B90]\]. It is not clear if hepatitis B combination therapy with tenofovir and lamivudine is more potent than monotherapy with tenofovir. A small randomized clinical trial on 36 patients and a large retrospective observational study failed to show any significant difference in HBV suppression between monotherapy and combination therapy\[[@B116],[@B117]\]. Conversely, another retrospective cohort analysis revealed a superior HBV suppression by lamivudine-tenofovir combination compared with tenofovir monotherapy\[[@B118]\]. In addition, a recent report provides evidence of the benefits of effective ART on virologic and clinical outcomes in HIV and HIV/HBV coinfection, especially regimens that contain potent HBV activity, such as tenofovir disoproxil fumarate (TDF)\[[@B119]\]. However, Boyd et al\[[@B74]\] reported that liver fibrosis decreases only in a small number of HIV-HBV co-infected patients during TDF.

According to Guidelines for the Use of Antiviral Agents in Adults and Adolescents Living with HIV\[[@B120]\], all people with HIV should be screened for HCV. ART slows down the progression of liver disease, and its benefits outweigh concerns regarding the drug-drug interaction. However, drug-drug interactions should be taken into consideration. All HCV/HIV-infected patients should be evaluated for HCV therapy. These patients also need to be screened for HBV since HBV reactivation may happen during HCV treatment with DAA. Persons with HCV/HIV co-infection and active HBV infection should receive ART that includes two agents with anti-HBV activity prior to initiation of HCV therapy.

Significant accomplishments were made in HIV and HCV research during the last 20 years. ART introduction contributed to substantial decrease in HIV-related disease and death. Likewise, better understanding of the hepatotropic virus life cycle and virus-host interactions opened the avenues for the advancement of antiviral drugs accompanied with improved rates of cure among HCV or HBV mono-infected as well as HIV and HCV/HBV co-infected patients. Furthermore, new insight has been made into the multiple mechanisms of HIV and HCV/HBV pathogenesis leading to enhanced disease progression. Despite these developments, HCV or HBV and HIV co-infection continue to cause accelerated liver disease and death in these patients\[[@B90]\].

CONCLUSION
==========

The mechanisms that drives the progressive liver disease in HIV/HCV and HIV/HBV co-infections are multi-factorial, which includes HIV induced immune suppression due to CD4^+^ T-cell depletion, systemic immune activation, increased lymphocyte and hepatocyte apoptosis, oxidative stress, inflammation, impaired immune responses, promotion of retroviral infection of HSC and Kupffer cells and microbial translocation (Figure [1](#F1){ref-type="fig"}). Co-infection can complicate the treatment and management of HIV infection. Therefore, HIV infected patients co-infected with HBV or HCV should seek care from providers with expertise in the management of both HIV and hepatotropic viruses. In this regard, HIV and viral hepatitis testing should be followed by lifesaving care and treatment, which ensures the best possible health outcomes and prevents deaths among persons living with these co-infections.
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